Latest releases

Mar 20, 2018 ı Corporate Releases

Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Mar 16, 2018 ı Corporate Releases

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

View all releases

Join Lundbeck

Current open positions

Browse global vacancies

FY/Q4 financial results

Watch the investor presentation

 

Read the FY/Q4 release here

Latest feature

April 2018:

 

PatientView Report 2018: Strong global recognition of Lundbeck’s reputation

 

Read more

Corporate film

play

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders.

 

Share price

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.